-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Under the general trend of pharmaceutical innovation, it has long been the norm for pharmaceutical companies to join forces with each other, but it is worth noting that under this tide of cooperation, many pharmaceutical companies have announced that they will terminate the cooperati.
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data releas.
No further collaboration with Atara to develop mesothelin-targeted CAR-T cell therapy programs, including autologous ATA2271 and allogeneic ATA3271 CAR-T therapi.
According to public information, Bayer and Atara earlier reached a cooperation agreement of up to 670 million US dolla.
The collaboration includes financial support and development of ATA3271 (allogeneic T-cell immunotherapy) and autologous ATA2271 therapies for the treatment of mesothelin-high tumors such as malignant pleural mesothelioma and non-small cell lung canc.
However, at the end of February this year, Atara reported that it had voluntarily suspended the recruitment of new patients for mesothelin-targeted autologous CAR-T therapy because of a serious adverse event involving the death of a patient in a phase I clinical trial of ATA2271 thera.
(SAE.
It is understood that Bayer's decision to suspend cooperation will force Atara to make necessary changes to its CAR-T therapy product pipeline pl.
However, according to Pascal Touchon, president and CEO of Atara, Atara remains focused on the interim analysis of the EMBOLD study of ATA1882, which will be announced in June, and looks forward to the continued progress of tab-c.
In addition to Bayer, many companies have also announced the termination of cooperation agreements since the beginning of this ye.
On May 9, Johnson & Johnson announced that it had terminated its cooperation and licensing agreement with Bavarian Nord.
The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma vir.
Currently, J&J has not used the technology to develop a hepatitis B vacci.
On May 6, Innovent announced on the Hong Kong Stock Exchange that on January 14, 2020, the company signed a cooperation agreement with Coherus BioSciences, I.
to grant Coherus' bevacizumab biosimilar (IBI) -305) commercialization interests in the United States and Cana.
As a new development of this agreement, the company and Coherus have decided to terminate the agreement, and the company will take back the relevant rights and interests of IBI-30 The business decision was made after evaluating the North American market dynamics for bevacizumab biosimilars and development delays due to the ongoing pandem.
Innovent said that it is confident in the efficacy and safety of the drug, and this decision will not affect the arrangement of the product in other regio.
In addition, as early as January 4, Junshi Bio also issued an announcement of its voluntary disclosure of terminating the promotion cooperation agreement with AstraZeneca Pharmaceutica.
The announcement stated that as the commercialization team built by Junshi Bio gradually matured, more indications of its PD-1 product toripalimab injection were successfully included in the new version of the National Medical Insurance List, and the original cooperation agreement was terminated after the two parties negotiat.
It is understood that on February 28, 2021, Junshi Biotech and AstraZeneca signed the "Exclusive Promotion Agreement", and the listed company granted AstraZeneca Triprilimab Injection (trade name: Tuoyi) in mainland China The exclusive promotion rights for the indications in the field of urological oncology that are subsequently approved for listing in the region, as well as the exclusive promotion rights for all approved indications in non-core urban are.
On the whole, the division and combination of pharmaceutical companies have become the norm in the indust.
Focusing on medium and long-term development, this situation may become more and more frequent in the future as innovation and research and development are still the general trend of the indust.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data releas.
No further collaboration with Atara to develop mesothelin-targeted CAR-T cell therapy programs, including autologous ATA2271 and allogeneic ATA3271 CAR-T therapi.
According to public information, Bayer and Atara earlier reached a cooperation agreement of up to 670 million US dolla.
The collaboration includes financial support and development of ATA3271 (allogeneic T-cell immunotherapy) and autologous ATA2271 therapies for the treatment of mesothelin-high tumors such as malignant pleural mesothelioma and non-small cell lung canc.
However, at the end of February this year, Atara reported that it had voluntarily suspended the recruitment of new patients for mesothelin-targeted autologous CAR-T therapy because of a serious adverse event involving the death of a patient in a phase I clinical trial of ATA2271 thera.
(SAE.
It is understood that Bayer's decision to suspend cooperation will force Atara to make necessary changes to its CAR-T therapy product pipeline pl.
However, according to Pascal Touchon, president and CEO of Atara, Atara remains focused on the interim analysis of the EMBOLD study of ATA1882, which will be announced in June, and looks forward to the continued progress of tab-c.
In addition to Bayer, many companies have also announced the termination of cooperation agreements since the beginning of this ye.
On May 9, Johnson & Johnson announced that it had terminated its cooperation and licensing agreement with Bavarian Nord.
The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma vir.
Currently, J&J has not used the technology to develop a hepatitis B vacci.
On May 6, Innovent announced on the Hong Kong Stock Exchange that on January 14, 2020, the company signed a cooperation agreement with Coherus BioSciences, I.
to grant Coherus' bevacizumab biosimilar (IBI) -305) commercialization interests in the United States and Cana.
As a new development of this agreement, the company and Coherus have decided to terminate the agreement, and the company will take back the relevant rights and interests of IBI-30 The business decision was made after evaluating the North American market dynamics for bevacizumab biosimilars and development delays due to the ongoing pandem.
Innovent said that it is confident in the efficacy and safety of the drug, and this decision will not affect the arrangement of the product in other regio.
In addition, as early as January 4, Junshi Bio also issued an announcement of its voluntary disclosure of terminating the promotion cooperation agreement with AstraZeneca Pharmaceutica.
The announcement stated that as the commercialization team built by Junshi Bio gradually matured, more indications of its PD-1 product toripalimab injection were successfully included in the new version of the National Medical Insurance List, and the original cooperation agreement was terminated after the two parties negotiat.
It is understood that on February 28, 2021, Junshi Biotech and AstraZeneca signed the "Exclusive Promotion Agreement", and the listed company granted AstraZeneca Triprilimab Injection (trade name: Tuoyi) in mainland China The exclusive promotion rights for the indications in the field of urological oncology that are subsequently approved for listing in the region, as well as the exclusive promotion rights for all approved indications in non-core urban are.
On the whole, the division and combination of pharmaceutical companies have become the norm in the indust.
Focusing on medium and long-term development, this situation may become more and more frequent in the future as innovation and research and development are still the general trend of the indust.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
